A clinical, molecular genetics and pathological study of a FTDP-17 family with a heterozygous splicing variant c.823-10G>T at the intron 9/exon 10 of the MAPT gene

Diana A. Olszewska, Conor Fearon, Christopher McGuigan, Terri P McVeigh, Henry Houlden, James M Polke, Brian Lawlor, Robert Coen, Michael Hutchinson, Michael Hutton, Alan Beausang, Isabelle Delon, Francesca Brett, Ioanna Sevastou, Nuria Seto-Salvia, Rohan de Silva, Tim Lynch

A R T I C L E   I N F O

Article history:
Received 23 December 2020
Revised 17 April 2021
Accepted 13 May 2021
Available online 23 May 2021

Keywords:
c.823-10G>T
Intron 9/exon 10 mutation
Frontotemporal dementia
Genetics
Neuropathology

A B S T R A C T

We report the first clinical-radiological-genetic-molecular-pathological study of a kindred with c.823-10G>T MAPT intronic variant (rs63749974) associated with frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). We describe the clinical spectrum within this family and emphasize the association between MAPT gene variants and motor neuron disease. This report of a second family with FTDP-17 associated with c.823-10G>T MAPT variant strongly supports pathogenicity of the variant and confirms it is a 4-repeat (4R) tauopathy. This intronic point mutation, probably strengthens the polypyrimidine tract and alters the splicing of exon 10 (10 nucleotides into intron 9) close to the 3’ splice site.

© 2021 The Author(s). Published by Elsevier Inc.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

1. Introduction

In 1994, we reported an Irish-American family with frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) and termed this disorder disinhibition-dementia-parkinsonism-amyotrophy-complex (DDPAC) (Lynch et al., 1994; Wilhelmsen et al., 1994; Sima et al., 1996). This led to a clinical-radiological-pathological-genetic linkage study and ultimate cloning of the microtubule-associated protein tau gene (MAPT) on chromosome 17q21.31 (Hutton et al., 1998; Spillantini et al., 1998). Variants in MAPT are responsible for 15-20% of hereditary frontotemporal lobar degeneration (FTLD). Other common genetic causes of FTLD include progranulin (GRN) pathogenic
variants (20–25% of FTLD) and hexanucleotide expansion repeats in the open reading frame of chromosome 9 (C9orf72) gene (3–48% of FTLD depending on the report) ([DeJesus-Hernandez et al., 2011 Majounie E et al., 2012, McCarthy et al., 2015]). Of the genetic causes of FTLD, C9orf72, is most commonly associated with motor neuron disease (MND) (van Blitterswijk et al., 2013). However, as indicated by “amyotrophy” in DDPAC, MAPT variants are associated with later-onset MND (Moore et al., 2020).

Fifty-four pathogenic variants (coding, missense, deletions and intronic) (some close to the splice-donor site 3’ of the alternatively spliced exon 10), of MAPT have been identified (McCarthy et al., 2015). In 1998 we (Hutton et al., 1998) and others (Spillantini et al., 1998) identified the +14 C->T exon 10/intron 10 boundary MAPT variant in the DDPAC family. In 2015, we “closed the tau stem loop” by describing the ‘missing’ c.915+15A>C variant at the intronic boundary downstream of exon 10 (note that MAPT variants are described in this report according to RefSeq transcript NM_005910.5 – c.823-915 encodes exon 9 of this transcript, though it is commonly referred to as ‘exon 10’ of the MAPT gene according to an alternative exon numbering convention), in another Irish FTDP-17 family (Grover et al., 1999; Qian and Liu, 2014; McCarthy et al., 2015).

In 2006, the c.823–10G>T variant MAPT was reported in one FTDP-17 family (Malkani et al., 2006). However, it remained undetermined whether c.823–10G>T is a pathogenic or a benign intronic variant as there was no pathological proof of FTLD, nor was there molecular confirmation of a 4R tauopathy. There have been no subsequent reports of other FTDP-17 patient/families associated with this MAPT intronic variant. We now present a clinical-radiological-genetic-molecular-pathological study of an Irish FTLD family associated with the c.823–10G>T variant. Our kindred is the second family with c.823–10G>T variant co-segregating with FTDP-17. We present the first pathological study of a c.823–10G>T variant family, confirming that this variant results in altered MAPT exon 10 splicing leading to increased 4R tau and provide supportive evidence of pathogenicity of c.823–10G>T.

2. Materials and Methods

Mater Misericordiae University Hospital, Dublin granted the ethical approval. Informed consent was obtained. We conducted a detailed family study including chart review of family members and neurological examination of the proband (Fig. 1A III-1) and two siblings (Fig. 1A III-5, III-7). MRI brain imaging (Suppl. Fig. 1) of the proband (Fig. 1A III-1), genetic analysis of blood samples from the proband (Suppl. Fig. 1) and two unaffected siblings and necropsy of the proband (Fig. 1A III-1) and his brother (Fig.1A III-4) were performed (Fig. 3). The brain tissue was analysed using RT-PCR and Western blot (Fig. 4).

2.1. DNA sequencing

We performed Sanger sequencing using standard techniques and Mutation Surveyor software of exons 1–13 and intron boundaries of the MAPT gene (excluding exons 4a, 6, 8 which are not usually transcribed in the 6 major brain isoforms in the adult brain). The PCR primers used for exon 10 were FWD: 5’-AGGGTGCGCGCATGCTAC-3’; RVS: 5’-CCCAAGAGTTATTTCTATGC-3’, other primer sequences are available on request. The results were classified as per the American College of Medical Genetics and Genomics (ACMG) guidelines (Richards et al. 2015).

2.2. RT-PCR analysis

RNA was isolated from 3 brain sections (inferior parietal, mid striatum, thalamus) from the proband (Fig. 1A III-1) and control brains from a patient with a multiple system atrophy cerebellar subtype (MSA-C) and a patient with Pick’s disease (PiD) using TRizol™ (Life Technologies) and cDNA derived using Superscript III First-Strand Kit (Invitrogen). For PCR analysis of MAPT exon 10 splicing, we used primers from flanking exons: Forward (exon 9): 5’-GTCAAAGTCCAAGATCGGCCTC-3’ and Reverse (exon 13): 5’-TGCTCTGCTTGGCCGTTGGC-3’(Rodriguez-Martin et al. 2005). On agarose gels, we detected an intermediate band of approximately 380bp between those for the 3R and 4R-tau mRNA bands (305 bp and 397bp, respectively) (Fig. 4). To resolve this, we used the fluorescent FAM-labelled forward primer with capillary electrophoresis and confirmed that this is a heteroduplex artefact, as previously described (Grover et al, 1999; Kalbfuss et al. 2001).

2.3. Haplotype analysis

Additionally, we determined the MAPT haplotype in the proband, and his two unaffected siblings by testing for the presence of a 238-base pair deletion, characteristic of the H2 haplotype, located between exons 9 and 10 (Baker et al 1999). Genomic DNA was extracted from blood using standard techniques. The primers used were: Forward 5’-GGAGAGCTTTCGCTCTG-3’ and Reverse 5’-AGGAGCTTTCGCTCTG-3’. The analysis was performed using previous standard protocols (Sposito et al 2015).
Two controls (H1/H1 and H1/H2) were included to confirm the PCR was optimized for the detection of both haplotypes.

2.4. Western blot analysis

Sarkosyl-insoluble tau from the same brain sections was isolated as previously described (Goedert et al. 1992). Briefly, frozen brain was homogenized in buffer (10 mM Tris-HCl, pH=7.5, 0.8 M NaCl, 1 mM EDTA and 10% sucrose (10x vol (w/v)) and centrifuged for 10 min at 16,000 xg. After retaining supernatant, the pellet was re-homogenised in in 5x vol of homogenization buffer and re-centrifuged and supernatants pooled. N-lauroylsarcosinate (w/v; Sigma-Aldrich) was added to 1% (w/v) and samples rocked for 1h at room temperature. Sarkosyl-insoluble pellets were then obtained by centrifugation at 100,000 x g for 1h and resuspended in 50mM Tris-HCl buffer (pH=7.5). The samples were then subjected to Western blot and tau detected with rabbit anti-tau polyclonal antibody (Dako: 1/10,000) and 1D4Ye-800CW secondary antibody (Li-Cor) with imaging on a Li-Cor Odyssey Fc.

3. Results

3.1. Case series report

The proband (Fig. 1A: III-1) was an Irish man who ceased working as a cameraman aged 50 because of poor concentration. He became distant and laughed inappropriately. Aged 54 he developed tremor, stiffness and frequent falls followed by depression (age 60). He was diagnosed with FTD at 61. He was admitted to a nursing home and became wheelchair-dependent and anarthric. He had little response to Levodopa/Carbidopa. At age 61 his Montreal Cognitive Assessment (MoCA) test was 16/30. His cerebrospinal fluid (CSF) analysis showed slightly increased albumin 0.246 g/l (0.140-0.200), slightly low IgG at 0.017g/l (0.02-0.04), but normal IgG index 0.480 (0.0-0.7). CSF tau and amyloid were not studied. He died aged 65 and necropsy was performed (Fig. 3).

The proband had four brothers and two sisters (Fig. 1A), three of whom had early-onset dementia with a similar phenotype (Suppl. Table 1). One of the proband’s brothers (Fig. 1A: II-3) became “odd” in his forties, e.g. eating a half-eaten apple from a bin and making up stories. He was aggressive, “bossy”, intense and forgetful. He was diagnosed with FTD and died at a nursing home aged 59.

Another brother (Fig. 1A: III-4) also developed early-onset dementia (Suppl. Table 1). He became “odd” in his forties, paranoid and withdrawn. He indicated, “People feel I am like my brother” (Fig. 1A III-2). In his early fifties he failed to recognise familiar friends and was inattentive with personal hygiene. Parkinsonism was an early feature and fasciculations of face and trunk were noticed terminally. Aged 52, he scored 27/30 on a Mini-Mental State Examination (MMSE) decreasing to 22/30 eleven months later (Suppl. Table 2 additional testing). At age 53, he was admitted to a hospital with confusion, urinary incontinence and decreased consciousness. He developed type II respiratory failure requiring intubation and ventilation for apnoeic episodes. Fasciculations around the shoulders were detected and he was diagnosed with MND. He deteriorated, died from pneumonia and underwent autopsy.

The proband’s sister (Fig. 1A: III-6) became inappropriate and vulgar in public aged 50. She was impatient, forgetful and less talkative. She sometimes used the wrong word. She stopped socialising and often wore the same outfit daily. She developed a “sweet tooth” and became obsessive about security at home. She scored 21/30 on her MMSE points lost on orientation and recall) and had difficulty performing the Luria test. She described the cookie-jar picture in short hesitant sentences. She had difficulty naming faces but identified a United States President as such (Nixon). She described a pyramid as “a roof”, and an igloo “a little cave”. She had a monotonous voice, masked facies, slow smile and slow left shoulder shrug. There was mild rigidity, slower rapid alternating movements and decreased left arm swing. She died aged 61.

Three other siblings are not clinically affected. An unaffected brother (Fig. 1A:III-3) died from a lung cancer aged 49. Two other siblings are well including a 62-year-old brother (Fig. 1A:III-5) and a 77-year-old sister (Fig. 1A:III-7). Both had a normal neurological examination (except for bilateral postural and kinetic hand tremor in the brother). The brother scored 27/30 on MoCA and 16/18 Frontotemporal Assessment Battery (FAB) testing (sister MoCA 26/30, FAB 14/18). The unaffected siblings would be expected to have symptoms by now considering their age and a fully penetrant disorder.

The proband’s father (Fig. 1A:II-7) became short-tempered and forgetful aged 43. During his daughter’s wedding he asked, “Is this the chap she is getting married to”. He kept sweets in his pocket, was “childish”, depressed, made mistakes in his job, and attended multiple Sunday church services. He died aged 53. The proband’s mother (Fig. 1: II-8) developed dementia in the late 70s and died at 88. A necropsy was not carried out. A maternal aunt (Fig. 1A: II-10) developed dementia and died in a nursing home.

3.2. Neuroimaging

The proband’s MRI brain (Fig. 1A: III-1), (>10 years after onset), demonstrated severe bitemporal/moderate bifrontal atrophy with relative sparing of parieto-occipital lobes (Suppl. Fig. 1), atrophic corpus callosum and hydrocephalous ex-vacuo.

3.3. Neuropathological examination

3.3.1. Proband (Fig. 1A. III-1)

Macroscopic description: There was severe atrophy of frontal and temporal lobes with normal cortical ribbon throughout. Axial brainstem sections showed a pale substantia nigra.

Microscopy: There was marked cortical spongiosis and neuronal loss most marked in the superficial cortical laminae of the frontal, temporal lobes, insular cortex, anterior cingulate and less prominent in the parietal lobes and absent in the occipital lobes. Many of the residual cortical neurons were “ballooned neurons”. No Pick body-like inclusions were seen. The corpus callosum and subcortical/ventriculat white matter showed secondary degeneration. The midbrain (level of the red nucleus) showed loss of nigral pigmented neurons with pigmentary incontinence.

Frequent tau-immunopositive (AT8 monoclonal mouse anti-human PHF-tau pS202/pT205, Clone AT8, Innogen, dilution 1/2000) neuropil threads and neuronal inclusions were present in the cerebral cortex (frontal, temporal lobes, to a lesser extent in parietal and sparse in occipital lobes), basal ganglia, diencephalon, brainstem and dentate. Spherical tau-immunopositive inclusions were very frequent in the dentate fascia, amygdala, red nucleus, substantia nigra, periaqueductal grey matter and superior colliculus, the tegumentum, basis pontis and medulla. There was marked granular staining throughout the white matter and extremely frequent perinuclear cytoplasmic tau aggregations within oligodendrocytes. Three-repeat (3R)-tau staining (RD3 anti-tau monoclonal antibody, clone 8E6/C11, (Millipore) (de Silva et al. 2003) showed occasional
positive neuronal cytoplasmic inclusions, glial cytoplasmic inclusions and dystrophic neurites in the cerebral hemispheres, anterior striatum and midbrain. Four-repeat (4R)-tau staining (RD3 anti-tau monoclonal antibody, clone 1E1/A6, Millipore) (deSilva et al. 2003) revealed abundant neuronal cytoplasmic inclusions, glial cytoplasmic inclusions and dystrophic neurites in the same areas.

The features show 4R tauopathy and are consistent with those described in FTDP-17 (Fig. 3) (Sima et al. 1996).

3.3.2. The proband’s brother (Fig. 1A:III-4)

Macroscopic examination: There was no disproportionate frontal atrophy; however, there was hippocampal and temporal horn atrophy, together with asymmetry of spinal cord.

Microscopy: Spongiosis (laminae I–3) and mild-moderate astrocytic gliosis affecting temporal lobes more than frontal lobes were seen with similar changes in the hippocampus, amygdala, caudate, globus pallidus, substantia nigra and locus coeruleus. Occipital lobe was normal on H&E. There was anterior horn cell loss with gliosis in the spinal cord (cervical- and thoracic-predominant). 3R tau staining showed occasional positive inclusions. 4R tau staining demonstrated inclusions in the parahippocampal gyrus, both in astrocytes and neurons in the substantia nigra and locus coeruleus but no inclusions in the cerebellum or spinal cord. TDP-43 staining showed no evidence of accumulation in the cytoplasm and normal neuronal staining. Lewy bodies, neurofibrillary tangles and Pick body-like inclusions were absent. Thus, tau antibody staining for RD4/PHF confirm this as a 4R tauopathy (Fig. 3 I-K).

3.4. Muscle biopsies at autopsy (deltoid and quadriceps)

There were angular atrophic fibres scattered among fibres of normal size. Routine ATPase preparations showed type-I and type-2 fibre atrophy with evidence of fibre-type grouping (deltoid > quadriceps), consistent with deltoid and quadriceps denervation.

3.5. Genetic and Segregation analysis results

Sanger sequencing showed proband’s (Fig. 1A. III-1) heterozygosity for the splicing variant c.823-10G>T at the intron 9/exon 10 boundary of the MAPT gene (Fig. 1B and Fig. 2) not detected in the two asymptomatic siblings (III-5 and III-7).

3.6. RT-PCR and Western blot results

In order to assess the effect of the c.823-10G>T mutation on alternative splicing of MAPT exon 10, we used RT-PCR with primers in flanking exons 9 and 13. Compared to the controls, the proband’s brain showed an almost complete shift to exon 10-containing (4R-tau) transcript, particularly in the inferior parietal and mid striatum regions where the exon 10− (3R-tau) band is scarcely detectable. As expected, with a control MSA-C brain, we show equal ratio of exon 10+/exon 10− (4R/3R-tau), and with a PiD brain, we show clearly increased exon 10− (3R) tau (Fig. 4).

This strong shift in splicing of exon 10 is clearly reflected in the sarkosyl-insoluble pathological tau, with the proband almost exclusively displaying 4R-tau, particularly the 0N4R isoform (Fig. 4). The above MSA-C case showed equal 3R/4R-tau isoform ratios and the PiD case (PiD1) showed similar isoform ratios to MSA-C. A second PiD case (PiD2) had a corresponding, strong shift to elevated 3R-tau comprising mainly of 0N3R and 1N3R isoforms (Fig. 4). These data show that like other MAPT exon 10 splicing mutations, the c.823-10G>T mutation causes a 4R-tauopathy by increased exon 10 splicing with elevated levels of the more fibrillogenic 4R-tau (Fig. 4).

3.7. The haplotype analysis results

The haplotype analysis showed that the proband (III-1) was an H1 homozygote, and the unaffected siblings (III-5, III-7) were both H1H2 heterozygotes. The result, demonstrating that the variant was on the H1 background Figure 5.

4. Discussion

In the adult human brain, there are six tau isoforms distinguished by the presence or absence of 29 and 58 amino acids in the MAPT amino-terminal half and a 31 amino-acid repeat domain in the MAPT carboxy-terminal half encoded by exon 10 (Goedert et al. 1989, Spillantini et al. 1997, Hasegawa et al. 1998, Hong et al. 1998). The 31 amino-acid repeat domain is included in tau isoforms with four microtubule-binding repeats (4R-tau). In the
healthy adult brain, there is approximately an equal 3R-/4R-tau ratio (Malkani et al. 2006; AD/FTD database). Multiple exonic and intronic variants within and around exon 10 impact splicing and lead to increased production of exon 10-containing transcripts (Hutton et al. 1998), thus resulting in an increased ratio of 4R- to 3R-tau isoforms (Hutton et al. 1998). 4R-tau isoforms bind microtubules more robust and produce greater levels of microtubule assembly in vitro compared to 3R-tau isoforms (Strang et al. 2019). However, overproduction of the more “aggregation-prone” 4R-tau may lead to the eventual assembly of 4R-tau into toxic aggregates including the wide twisted ribbons observed in several families with these MAPT variants (Spillantini et al. 1997). There are two major non-recombinating MAPT haplotypes, H1 and H2, defined by a region of linkage disequilibrium of over 900 kb (Pastor et al. 2002). Both haplotypes influence MAPT expression and splicing and studies have established the overrepresentation of H1 haplotype in 4-repeat tauopathies such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) (Pastor et al. 2002). However, data in frontotemporal dementia as the group are conflicting (Dilliot et al. 2019).

The exon 10 intronic variants are located around the splice acceptor and donor sites. Variants on the 3’ end of exon 10 (5’ splice site), include c.915+3G>A, c.915+12C>T, c.915+13A>G, c.915+14C>T, c.915+15A>C and c.915+16C>T (Hutton et al. 1998, Varani et al. 1999, Yasuda et al. 2000, Miyamoto et al. 2001, McCarthy et al. 2015). A transgenic mouse expressing human MAPT carrying the c.915+16C>T variant has increased 4R-tau and tau pathology confirming that overproduction of 4R-tau leads to the development of tauopathies (Umeda et al. 2013).

The c.823-10G>T (-10) mutation, described here, was previously reported by Malkani et al. (2006) in the intronic region immediately upstream of exon 10. It is predicted to strengthen the poly(pyrimidine) tracts thus affecting the splicing of exon 10 close to the 3’ splice site (Malkani et al. 2016). The mutation replaces purine with pyrimidine which is sufficient to enhance exon inclusion to near-constitutive levels. This expands the range of mechanisms by which pathogenic mutations are known to increase MAPT exon 10 splicing and thus increasing levels of 4R-tau. Remarkably only one exonic mutation (delK280) has been shown to have the

Fig. 3. Post-mortem staining of the proband (III-1) A, B, C, D, E and proband’s brother I, J, K, L (monocular mouse anti-human PHF-Tau, Clone AT8, Innogen, dilution 1/2000) A: Tau-immunopositive neurit thread and neuronal cytoplasmic aggregates (tangles), × 60, B: Tau-immunopositive neurit threads, diffuse neuronal Tau cytoplasmic immunopositivity (pretangles) (red arrow), × 60, C: White matter granular deposits and coiled Tau oligodendrocyte inclusions, × 60 mag, D: Circumferential Tau inclusions, dentate fascia neurons of hippocampus, × 20 mag, E: Neurofibrillary tangles and neurit threads, dentate nucleus of cerebellum, × 20 mag, F and G: H&E stain, cytoplasm distended / balloonned with basophilic refractile material × 60 mag, F: Neurons in temporal cortex, G: Superior frontal cortex, H: Substantia nigra with loss of pigmented neurons, gliosis and pigment incontinence, × 2 mag, H&E. Absent Pick bodies I 4 R Tau as deposits in neurones and coiled bodies in substantia nigra (yellow arrow) and threads (black arrow), x 40 J: 4R Tau in pontine nuclei neurones (black arrow) and as coiled bodies (yellow arrow) × 40, K: 4R Tau in parahippocampus gyrus in neurones (black arrow) and as coiled bodies (yellow arrow) × 60. (Color version of the figure is available online.)

Fig. 4. A Proband (III-1): RT-PCR with RNA isolated from 3 brain sections (inferior parietal, mid striatum, thalamus) with primers flanking MAPT exon 10. The two PCR products at 397bp and 305bp correspond to 4R-tau (exon 10+) and 3R-tau (exon 10-) mRNA, respectively. Note doublet with 4R-tau (exon 10+) band (397bp) with intermediate band of about 380bp between those for the 3R and 4R-tau mRNA bands (305 bp and 397bp, respectively). Using capillary electrophoresis of fluorescence FAM-labelled PCR product, we confirmed that this is a heteroduplex artefact, as previously described (Grover et al. 1999, Kalbluss et al. 2001). Two controls (MSA-C and PD were included in the analysis). The proband showed distinctly increased 4R:3R-tau mRNA ratio compared with the controls. B ImmunobLOTS of dephosphorylated sarkosyl-insoluble tau extracted from 3 brain regions sections (inferior parietal, mid striatum, thalamus) and compared to control patients with MSA-C (1 sample), Pick’s disease (2 samples). The insoluble pathological tau from the proband was almost exclusively 4R-tau.
opposite effect of reducing exon 10 incorporation and increasing 3R-tau, this is despite the multitude of positions at which mutations could occur that would cause reduced splicing (van Swieten et al. 2007). Moreover, interpretation of the delK280 mutation effect on splicing is complicated by the amino acid sequence change that also occurs with this mutation and which is known to dramatically reduce microtubule binding (van Swieten et al. 2007). In addition, in concert with the report by Malkani and colleagues (Malkani et al. 2006), we show that c.823-10G>T variant is on the H1 allele which presents the possibility of a common founder. Overall our findings add further support for a pathogenic model for the exon 10 splicing mutations where the absolute increase in 4R-tau and its associated consequences, most obviously increased aggregation, that ultimately cause FTDP-17 rather than a shift in the 4R:3R tau ratio.

In our family the proband’s brother (III-4) was admitted with type II respiratory failure with periods of apnoea and fasciculations leading to a diagnosis of MND. The necropsy did not show diaphragmatic denervation, but demonstrated anterior horn cell loss, more severe in the cervical and thoracic region. This is a very similar observation to the pathology found in the DDPAC family where the two spinal cords studied had anterior horn cell loss and one of the patients had fasciculations, muscle wasting, weakness, clonus and diffuse denervation on EMG (Lynch et al. 1994). This same patient developed a central hypoventilation syndrome requiring tracheostomy and phrenic nerve pacemaker (Ondine’s curse) (Lynch et al. 1994).

As mentioned earlier, C9orf72 is the most common cause of FTD associated with amyotrophic lateral sclerosis (FTD-ALS), reported by Moore and colleagues (Moore et al. 2020) in 11.1% (n=157) of 1433 C9orf72 carriers and ALS alone in 19.3% (n=276). MAPT gene associations with both FTD and ALS is much rarer, however, it occurs (FTD-ALS: 0.3% (2/729) and ALS: 0.1% (1/791)) especially with later development of ALS in patients with FTD (Lynch et al. 1994). MAPT variants in FTD and ALS should be kept in mind in C9orf72-negative patients (Moore et al. 2020).

The proband from the first FTDP-17 family reported with the c.823-10G>T MAPT variant that co-segregated with the disease was a 55-year-old man with progressive memory loss, outbursts of anger, emotional lability and disinhibition (Malkani et al. 2006). He had no parkinsonism, and his brain MRI was normal. The proband’s sister was a 45-year-old woman who spent money compulsively from the age of 38. She was obsessed with house chores and developed memory loss and hypophonia. The proband’s father had memory problems from age 41, anger outbursts and poor social skills. He was in a nursing home from age 44 and died aged 50. However, there was no neuropathological data available from this pedigree to confirm the diagnosis of FTLD (Malkani et al. 2006, AD/FTD database, Maffucci et al. 2019). There has been no other patient reported since 2006 to confirm or refute c.823-10G>T as a causative MAPT variant of FTDP-17.

Segregation information in our family (2 informative meioses) and in the previously reported family (3 informative meioses) (Malkani et al. 2006) (ACMG PP1-2 families) (Richards et al. 2015) is strongly supportive of pathogenicity (Moore et al. 2020). This finding, in combination with a supportive phenotype of 4R taurapathy at autopsy (ACMG PP4) (Richards et al. 2015), and functional studies (ACMG PS3) support the premise that c.823-10G>T MAPT variant is pathogenic. Other supporting factors include the location of the variant in relation to the poly pyrimidine tract in intron 9 (in silico prediction software predict +60.4% (MAXEnt) (Ye et al. 2004), +41.6% (Splice Site Prediction by Neural Network- NNSPLICE (Reese et al. 1997) and +8.3% (Splice Site Finder-SSF (Shapiro and Senapathy, 1987), change at the acceptor site 10bps downstream-ACMG (PP3-not used as PS3 provides a stronger evidence (Rodriguez-Martin et al. 2005)), the absence of this variant in population databases e.g. GnomAD (Karczewski et al. 2020), and no clinical significance in ClinVar (Landrum et al. 2020) -ACMG PM2). Moreover, the neuropathological examination of the patient with c.823-10G>T MAPT variant confirms FTLD and the pathology was very similar to other FTDP-17 patients (Olzsiewska et al. 2016). Finally, we performed a molecular study on brain tissue from the proband confirming a 4-repeat taurapathy.

5. Conclusion

We expand the phenotype and describe a second family with autosomal dominant 4-repeat FTDP-17 taurapathy associated with the MAPT c.823-10G>T intronic variant and, for the first time, present pathological and molecular evidence that this variant is pathogenic. This is the first description of a family with c.823-10G>T MAPT variant accompanied by necropsy and the first description of the MND associated with c.823-10G>T MAPT variant.

Data availability

All data pertaining to this manuscript will be available upon reasonable request.

Acknowledgements

We would like to express our sincere appreciation to the patients and families for their time, effort and participation.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

NSS is funded by the Reta Lila Weston Trust for Medical Research, CBD Solutions, MRC and Rosetrees Trust.
The authors of this manuscript declare that there are no competing interests.

Supplementary materials

Supplementary material associated with this article can be found in the online version, at doi:10.1016/j.nrl.2021.05.010.

References

Baker, M., Litvan, I., Hulshen, H., Johnston, D., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., Hutton, M., 1999. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8, 715–717.

De Salvo, R., Lashley, T., Gibb, G., Hanger, D., Hope, A., Reid, A., Bandopadhyay, R., Utton, M., Strand, C., Jowett, T., Khan, N., Anderton, B., Wood, N., Holton, J., Revesz, T., Lees, A., 2003 Jun. Pathological inclusion bodies in tauopathies contain distinct complements of tau with or without microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 29 (3), 288–302.

Dejesus-Hernandez, M., Mackenzie, IR, Boone, BF, Boxer, A.L., Baker, M., Rutherford, NJ, Nicholson, AM, Finch, NA, Flynn, H., Johnson, AD, Journei, N., Wojtas, A., Sengiy, P., Hisung, GY, Karydas, A., Seeley, WY, Josephs, KA, Coppola, G., Geschwind, DH, Wiszek, ZK, Fieldman, H., Knopman, DS, Petersen, RC, Miller, BL, Dickson, DW, Boylan, K.B., Graff-Radford, NR, Rademakers, R., 2011. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 69(2), 245–256.

Dillott, AA, Evans, EC, Farhan, SM, Ghanji, P., Sato, C., Zhang, M., McIntyre, AD, Cao, H., Racacho, L., Robinson, JP, Strong, MJ, Masellis, M., Bulman, DE, Rogaeva, E., Black, SE, Finger, E., Frank, A., Freedman, M., Hassan, A., Lang, A., Shooshimeh, CL, Swartz, RH, Tang-Wai, D., Tartaglia, MC, Turnbull, J., Zimmah, L., Hegele, RA, ONN-DRI Investigators, 2019 Sep. Genetic Variation in the Ontario Neurodegenerative Disease Research Initiative. Can J Neurol Sci 46 (5), 491–496.

Goedert, M., Spillantini, MC, Jakes, R., Rutherford, D., Crowther, RA., 1989. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neurosc 34 (3), 519–526.

Goedert, M., Spillantini, MC, Cairns, NJ, Crowther, RA., 1992. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuros 8 (1), 159–168.

Grouv, A., Houghen, H., Baker, M., Hoxton, M., Lewis, J., Frihar, G., Pickering-Brown, S., Duff, K., Hutton, M., 1999 May 21. S’-splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J Biol Chem 274 (21), 15134–15143.

Hanger, DP, Gibb, CM, de Silva, R., Boutajangout, A., Brion, JP, Revesz, T., Lees, AJ, Anderton, B., 2002 Nov. The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies. FEBS Lett. 531 (3), 538–542.

Hasegawa, M., Smith, MJ, Goedert, M., 2013 Oct. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Letters 437 (3), 207–210.

Hong, M., Zhukareva, V., Vogelsberg-Ragaglia, V., Wiszek, Z., Reed, L., Miller, BI, Geschwind, DH, Bird, TD, McKeed, D., Goate, A., Morris, JC, Wilhelmsen, KC, Schellenberg, GD, Trojanowski, JQ, Lee, VM., 1998 Dec. 4 Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282 (5395), 1914–1917.

Hutton, M., Lendon, CL, Rizzu, P., Baker, M., Froehlich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., Hackett, J., Johnson, J., Lins, C., Solcis, D., Dickson, D., Davies, P., Petersen, KC, Stevens, M., de Graaff, E., Wauters, E., van Baren, J., Hillelebrand, M., Joose, M., Kwon, JM, Nowotny, P., Che, LK, Norton, J., Morris, JC, Reed, LA, Trojanowski, J., Basun, H., Lannfelt, L., Neustad, M., Fahn, S., Dark, F., Tannenberg, T., Todd, PR, Hayward, N., Kwok, JB, Scheffler, PF, Andreadis, A., Snowden, J., Crujard, D., Neary, D., Owen, F., BA, Hardy, J., Goate, A., van Swieten, J., Mann, D., Lynch, T., Heutink, P., 1998 Jun. Association of missense and splice-site mutations in tau with the inherited dementia FTDP-17. Science 280 (5395), 1914–1917.

Kalbfuss, B., Mabon, SA, Misteli, T., 2001 Nov. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J Biol Chem 276 (46), 42986–42993.
Richards, S. Aziz, N. Bale, S. Bick, D. Das, S. Gastier-Foster, J. Grody, WW. Hegde, M. Lyon, E. Spector, E. Vooelkerding, K. Rehm, HL. 2015 May. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17 (5), 405–424.

Rodriguez-Martin, T. Garcia-Blanco, MA. Mansfield, SG. Grover, AC. Hutton, M. Yu, Q. Zhou, J. Anderton, BH. Gallo, JM. 2005 Oct 25. Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies. Proc Natl Acad Sci U S A 102 (43), 15659–15664.

Shapiro, MB. Senapathy, P. 1987. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res. 15, 7155–7174.

Sima, AA. Defendini, R. Keehane, C. D’Amato, C. Foster, NL. Parchi, P. Gambetti, P. Lynch, T. Wilhelmsen, KC. 1996 Jun. The neuropathology of chromosome 17-linked dementia. Ann Neurol 39 (6), 734–743.

Spillantini, MG. Goedert, M. Crowther, RA. Murrell, JR. Farlow, MJ. Ghetti, B. 1997. Familial multiple system tauopathy with presenile dementia: A disease with abundant neuronal and glial tau filaments. Proc. Natl. Acad. Sci. USA 94, 4113–4118.

Spillantini, MG. Murrell, JG. Goedert, M. Farlow, MR. Klug, A. Ghetti, B. 1998. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA 95, 7737–7741.

Strang, KH. Golde, TE. Giasson, BI. 2019. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab Invest 99, 912–928.

Umeda, T. Yamashita, T. Kimura, T. 2013 Jul. Neurodegenerative disorder FTDP-17-related tau intron 10 +16C → T mutation increases tau exon 10 splicing and causes tauopathy in transgenic mice. Am J Pathol 183 (1), 231–225.

Wilhelmsen, KC. Lynch, T. Pavlov, E. Higgins, M. Nyaarda, TG. 1994. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 55, 1159–1165.

van Blitterswijk, M. DeJesus-Hernandez, M. Nienantsverdriet, E. Murray, ME. Heckman, MG. Diehl, NN. Brown, PH. Baker, MC. Finch, NA. Bauer, PD. Serrano, G. Beach, TG. Josephs, KA. Knopman, DS. Petersen, RC. Boeve, BF. Graff-Radford, NR. Boylan, KB. Petrucelli, L. Dickson, DW. Rademakers, R. 2013 Oct. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 12 (10), 978–988.

van Swieten, JC. Bronner, IF. Azmani, A. Severijnen, LA. Kamphorst, W. Ravid, R. Rizzu, P. Wijers, R. Heutink, P. 2007 Jan. The DeltaK280 mutation in MAP tau favors exon 10 skipping in vivo. J Neuropathol Exp Neurol 66 (1), 17–25.

Varani, L. Hasegawa, M. Spillantini, MG. Smith, MJ. Murrell, JR. Ghetti, B. Klug, A. Goedert, M. Varani, G. 1999 Jul 6. Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. Proc Natl Acad Sci U S A. 96 (14), 8229–8234.

Yasuda, M. Takamatsu, J. D’Souza, I. Crowther, RA. Kawamata, T. Hasegawa, M. Hasegawa, H. Spillantini, MG. Tanimukai, S. Poerkaj, P. Varani, L. Varani, G. Iwatsubo, T. Goedert, M. Schellenberg, DG. Tanaka, C. 2000 Apr. A novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). Ann Neurol 47 (4), 422–429.

Yeo, G. Burge, CB. 2004. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J. Comput. Biol. 11, 377–394.